Approval for adding quantitative determination of total antibodies to hepatitis b surface antigen in human adult, adolescent, and pediatric serum or plasma to the intended use. the device, as modified, will be marketed under the trade name advia centaur anti-hbs(ahbs) assay on centaur cp and is indicated for: advia centaur anti-hbs (ahbs) assay on the centaur cp analyzer: the advia centaur anti-hbs assay is an in vitro diagnostic immunoassay for the qualitative and quantitative determination of total antibodies to hepatitis b surfaceantigen in human adult, adolescent, and pediatric serum or plasma (edta or heparinized) using the advia centaur cp system. the assay results may be used as an aid in thedetermination of susceptibility to hepatitis b virus (hbv) infection in individuals prior toor following hbv vaccination or where vaccination status is unknown. assay results maybe used with other hbv serological markers for the laboratory diagnosis of hbv diseaseassociated with hbv infection. a reactive assay result will allow a differential diagnosis in individuals displaying signs and symptoms of hepatitis in whom etiology is unknown.